A goal of current research is to identify the role of mTOR inhibition in neurologic and developmental disorders beyond that of TSC (e.g., Leigh syndrome, Down syndrome, and neurofibromatosis types 1 and 2), which nonetheless share a common feature of mTOR pathway hyperactivation. The gene discussed is TSC1; the disease is neurofibromatosis type 1.